Braver Wealth Management buys $4 Million stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Braver Wealth Management scooped up 101,487 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 106,252 shares of Abbott Laboratories which is valued at $4 Million.Abbott Laboratories makes up approximately 0.66% of Braver Wealth Management’s portfolio.

Other Hedge Funds, Including , Argent Trust Co sold out all of its stake in ABT during the most recent quarter. The investment firm sold 33,534 shares of ABT which is valued $1.3 Million.Sentry Investment Management boosted its stake in ABT in the latest quarter, The investment management firm added 1,665 additional shares and now holds a total of 115,421 shares of Abbott Laboratories which is valued at $4.3 Million. Abbott Laboratories makes up approx 0.20% of Sentry Investment Management’s portfolio.Dillon Associates Inc boosted its stake in ABT in the latest quarter, The investment management firm added 2,191 additional shares and now holds a total of 184,263 shares of Abbott Laboratories which is valued at $7 Million. Abbott Laboratories makes up approx 3.29% of Dillon Associates Inc’s portfolio.

Abbott Laboratories opened for trading at $38.06 and hit $38.77 on the upside on Wednesday, eventually ending the session at $38.68, with a gain of 1.84% or 0.7 points. The heightened volatility saw the trading volume jump to 1,61,41,174 shares. Company has a market cap of $56,827 M.

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.